Abbott has reported that its ID NOW Covid-19 rapid test showed strong agreement to lab-based molecular polymerase chain reaction (PCR) instruments based on an interim analysis of an ongoing multi-site clinical study in urgent care clinics.

Launched in 2014, ID NOW is a rapid, instrument-based, isothermal system for the qualitative detection of infectious diseases. It is a molecular point-of-care platform for Influenza A & B, Strep A and RSV testing in the US.

Compared to two different lab-based PCR reference methods, the data from the interim results demonstrated ≥94.7% sensitivity and ≥98.6% specificity of the test.

The study evaluated samples from 256 patients and compared the results to a test developed by the US Centers for Disease Control and Prevention (CDC).

Abbott Rapid Diagnostics infectious disease senior medical director Philip Ginsburg said: “We are pleased that ID NOW is delivering on what it was designed to do – quickly detect the virus in people who need to know now if they are infected.

“This is great news for people who are experiencing symptoms and want to take action before they infect others, reducing the spread of infection in society.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The test delivers results quickly and helps to reduce the spread of infection by detecting Covid-19-positive patients faster.

The Everett Clinic in Washington, US, and an ongoing study of hospitalised and nursing home patients sponsored by Abbott also suggest that ID NOW performs best in patients tested earlier post-symptom onset.

The studies analysed ID NOW with variations in patient populations based on the number of days a patient was tested after first experiencing symptoms.